Published in Cancer Immun on June 26, 2007
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood (2009) 1.35
p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol (2009) 0.99
Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology (2015) 0.98
The type of lymphocyte infiltration near urothelial carcinoma is diagnostic for chronic lymphocytic leukemia. Urol Ann (2013) 0.92
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. J Natl Cancer Inst (2016) 0.91
Hepatocellular carcinoma with immature T-cell (T-lymphoblastic) proliferation. J Korean Med Sci (2010) 0.90
The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction. BMC Cancer (2010) 0.85
Immunotherapy for urothelial carcinoma: current status and perspectives. Cancers (Basel) (2011) 0.83
A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF. J Cell Mol Med (2009) 0.82
Decreased intratumoral Foxp3 Tregs and increased dendritic cell density by neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer. Int J Clin Exp Pathol (2014) 0.82
Chronic inflammation in urothelial bladder cancer. Virchows Arch (2015) 0.79
B7-H4's role "beyond the tumor". Inflammation (2013) 0.78
Leveraging fluorinated glucosamine action to boost antitumor immunity. Curr Opin Immunol (2012) 0.78
Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles. Nat Commun (2016) 0.78
Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics. Int J Clin Exp Pathol (2015) 0.78
Correlation of tumor-associated macrophages and NK cells with bladder cancer size and T stage in patients with solitary low-grade urothelial carcinoma. Wien Klin Wochenschr (2015) 0.77
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. Cancers (Basel) (2011) 0.77
Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy (2016) 0.77
Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int (2015) 0.76
Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma. Virchows Arch (2015) 0.76
Rab25 Small GTPase Mediates Secretion of Tumor Necrosis Factor Receptor Superfamily Member 11b (osteoprotegerin) Protecting Cancer Cells from Effects of TRAIL. J Genet Syndr Gene Ther (2013) 0.75
CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer. Oncogene (2016) 0.75
Smoking-induced immune deviation contributes to progression of bladder and other cancers. Oncoimmunology (2015) 0.75
How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open (2017) 0.75
Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer. Virchows Arch (2014) 0.75
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med (1996) 3.56
A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2.87
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun (2000) 2.10
Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer (2002) 2.10
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res (1993) 1.95
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med (2000) 1.67
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
Production of beta 2-microglobulin by normal and malignant human cell lines and peripheral lymphocytes. Transplant Rev (1974) 1.57
Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res (1999) 1.55
Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res (1986) 1.50
Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res (2002) 1.45
Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol (2001) 1.36
Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: its identification as Tn antigen. Proc Natl Acad Sci U S A (1985) 1.35
The Fas counterattack: cancer as a site of immune privilege. Immunol Today (1999) 1.28
Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol (2000) 1.23
CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol (1999) 1.19
Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol (2005) 1.19
Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol (1990) 1.19
Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer (1992) 1.18
Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res (1991) 1.17
Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother (1992) 1.15
Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol (1995) 1.14
Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev (1991) 1.14
CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J Immunol (2001) 1.09
CD95 ligand in graft rejection. Nature (1996) 1.09
Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res (2003) 1.03
Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res (1996) 1.01
Loss of beta2 microglobulin from the cell surface of cutaneous malignant and premalignant lesions. Br J Dermatol (1981) 0.98
Blood group precursor T-antigen expression in human urinary bladder carcinoma. Am J Clin Pathol (1982) 0.94
Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol (1986) 0.94
Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cell Immunol (1998) 0.91
Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res (1997) 0.90
The presence of beta2 microglobulin on the membrane of the keratinocyte in premalignant skin disorders. Br J Dermatol (1981) 0.89
Immunocompetence of tissue infiltrating lymphocytes in bladder tumors. J Urol (1988) 0.89
Dissociation of HLA heavy chain and light chain (beta 2 microglobulin) expression on the cell surface of cutaneous malignancies. Br J Dermatol (1983) 0.87
Impact of human bladder cancer cell architecture on autologous T-lymphocyte activation. Int J Cancer (2002) 0.87
Clinical studies on cell-mediated immunity in patients with urinary bladder carcinoma: blastogenic response, interleukin-2 production and interferon-gamma production of lymphocytes. Br J Urol (1990) 0.86
Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol (2003) 0.86
Plenary lecture: lymphocytic infiltration in relationship to urologic tumors. Natl Cancer Inst Monogr (1978) 0.84
Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder. J Urol (1990) 0.83
Analysis of natural killer activity and natural killer cell subsets in patients with bladder cancer. Cancer Immunol Immunother (1990) 0.82
MHC-dependent cytolysis of autologous tumor cells by lymphocytes infiltrating urothelial carcinomas. Int J Cancer (1997) 0.81
Tumor-infiltrating lymphocytes from nonrenal urological malignancies. Cancer Immunol Immunother (1990) 0.80
T-zone histiocytes and recurrence of papillary urothelial bladder carcinoma. Urol Int (1989) 0.78
Immunology of the bladder. Urol Clin North Am (1992) 0.77
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer (2002) 1.95
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med (2007) 1.92
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A (2009) 1.74
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol (2002) 1.74
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res (2011) 1.56
Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res (2004) 1.56
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol (2007) 1.53
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate (2012) 1.53
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov (2011) 1.52
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res (2010) 1.46
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol (2005) 1.44
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res (2007) 1.42
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res (2003) 1.42
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol (2008) 1.40
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol (2004) 1.39
Harnessing the power of the immune system to target cancer. Annu Rev Med (2012) 1.33
A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res (2010) 1.32
Bortezomib as a potential treatment for prostate cancer. Cancer Res (2004) 1.29
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res (2013) 1.29
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs (2011) 1.24
Adipose tissue-derived stem cells promote prostate tumor growth. Prostate (2010) 1.22
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One (2009) 1.20
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med (2014) 1.18
Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res (2011) 1.15
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 1.14
Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics (2009) 1.11
Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem (2004) 1.10
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A (2011) 1.09
p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis (2002) 1.08
A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res (2007) 1.07
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol (2002) 1.06
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol (2009) 1.05
The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res (2002) 1.04
Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol (2005) 1.03
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol (2011) 1.01
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res (2013) 1.01
Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer. Cancer Inform (2007) 0.99
Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep (2003) 0.99
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res (2005) 0.98
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer (2013) 0.98
Advances in the development of cancer immunotherapies. Trends Immunol (2012) 0.96
High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res (2004) 0.95
Prioritizing genes associated with prostate cancer development. BMC Cancer (2010) 0.94
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int (2009) 0.94
Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov (2011) 0.93
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun (2008) 0.93
Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res (2004) 0.93
Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer (2013) 0.92
Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther (2009) 0.91
Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev (2004) 0.91
Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia (2005) 0.91
Housekeeping genes in prostate tumorigenesis. Int J Cancer (2009) 0.90
Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy (2011) 0.90
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys (2012) 0.89
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer (2006) 0.88
Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol (2009) 0.88
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther (2009) 0.88
Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One (2012) 0.88
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res (2008) 0.87
Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate (2007) 0.87
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol (2003) 0.87
Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol (2010) 0.86
Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One (2011) 0.86
Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw (2006) 0.85
Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines (2010) 0.84
Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol (2004) 0.84
Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate (2004) 0.84